April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain free of clinical relapses and new or worsening brain lesions, according to one-year data from the Phase 3 OCARINA II study. Given twice a year as a 10-minute injection, this formulation of Ocrevus…
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada Viatris has launched a generic version of low-dose Copaxone (glatiramer acetate) in the Canadian market for the treatment of people with relapsing-remitting multiple sclerosis (RRMS) who retain the ability to walk. Called Glatiramer Acetate Injection 20 mg/mL, the product was approved in Canada as a generic of…
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment. That’s according to new data from the ULTIMATE Phase 3 trials,…
April 22, 2024 Columns by Desiree Lama Learning to manage cognitive impairment with multiple sclerosis Upon commencing my undergraduate studies at the University of Texas (UT) at Austin, I pursued a major in prehealth neuroscience. I had decided to pursue this degree shortly after my diagnosis of relapsing-remitting multiple sclerosis in 2016, during my senior year of high school. My hope in choosing the…